Get the Stockscreener App
6.545
3.56%
0.225
After Hours:
6.52
-0.025
-0.38%
22nd Century Group, Inc. stock is traded at $6.545, with a volume of 109.54K.
It is up +3.56% in the last 24 hours and down -43.68% over the past month.
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
See More
Previous Close:
$6.32
Open:
$6.42
24h Volume:
109.54K
Relative Volume:
1.63
Market Cap:
$2.26M
Revenue:
$15.74M
Net Income/Loss:
$-12.86M
P/E Ratio:
-0.0283
EPS:
-231.1302
Net Cash Flow:
$-8.71M
1W Performance:
-29.26%
1M Performance:
-43.68%
6M Performance:
-97.92%
1Y Performance:
-96.69%
1-Day Range:
$6.3204
$7.32
1-Week Range:
$5.414
$10.71
52-Week Range:
$5.414
$3,360.00
22nd Century Group, Inc. Stock (XXII) Company Profile
Name
22nd Century Group, Inc.
Sector
Industry
Phone
716-270-1523
Address
8560 Main Street, Williamsville, NY
Compare XXII vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XXII
22nd Century Group, Inc.
|
6.545 | 109.06K | 15.74M | -12.86M | -8.71M | -231.13 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
22nd Century Group, Inc. Stock (XXII) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-22 | Initiated | Alliance Global Partners | Buy |
| Jun-15-22 | Initiated | Craig Hallum | Buy |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Jul-23-21 | Initiated | Cowen | Outperform |
| Oct-16-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-11-16 | Reiterated | Chardan Capital Markets | Buy |
View All
22nd Century Group, Inc. Stock (XXII) Latest News
3.02M warrant shares registered for resale by 22nd Century (XXII) - Stock Titan
Shareholder voting outcomes at 22nd Century Group (NASDAQ: XXII) - Stock Titan
22nd Century Group announces warrant inducement and 1-for-20 reverse stock split By Investing.com - Investing.com Australia
Warrant inducement and 1-for-20 reverse split at 22nd Century Group (XXII) - Stock Titan
22nd Century Group announces warrant inducement and 1-for-20 reverse stock split - Investing.com UK
22nd Century Raises $0.46M via Warrant Inducement, Redeems $2.01M Preferred; Hires Dawson James - TradingView
22nd Century (NASDAQ: XXII) sets warrant inducement and 1-for-20 split - Stock Titan
XXII Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
XXII News | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
XXII Stock Chart | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
22nd Century launches VLN cigarettes in California stores - Investing.com UK
22nd Century launches VLN cigarettes in California stores By Investing.com - Investing.com South Africa
22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes - The Manila Times
FDA-authorized low-nicotine cigarettes begin California test run - Stock Titan
XXII Stock Price, Quote & Chart | 22ND CENTURY GROUP INC (NASDAQ:XXII) - ChartMill
22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers - Sahm
22nd Century Group (Nasdaq: XXII) Expands High-Margin - GlobeNewswire
22nd Century Group, IncCommon Stock (NQ: XXII - FinancialContent
22nd Century Group Expands Distribution of VLN® Cigarettes to 150 New Locations in Metro New York and Northern New Jersey - Quiver Quantitative
22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand - The Manila Times
22nd Century Group (Nasdaq: XXII) Ignites Major VLN Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand - Moomoo
FDA-authorized low-nicotine cigarettes target 800k NYC-area smokers - Stock Titan
22nd Century Group, Inc. (NASDAQ:XXII) Q1 2026 Earnings Call Transcript - Insider Monkey
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications - 2Firsts
22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review - The Manila Times
22nd Century Group Seeks FDA Renewal for VLN® as Modified Risk Tobacco Product - geneonline.com
XXII | 22nd Century Group Inc. FinancialsIncome Statement - Quiver Quantitative
22nd Century Group Seeks Renewal of Modified Risk Tobacco Product Status for VLN® King and VLN® Menthol King Cigarettes - Quiver Quantitative
Cigarettes with 95% less nicotine face new FDA review - Stock Titan
Fda to review two modified risk tobacco product renewal applications from 22nd Century Group - marketscreener.com
FDA To Review Two Modified Risk Tobacco Product Renewal Applications From 22nd Century Group - TradingView
22nd Century slightly lowers first-quarter loss; no net revenue from very-low-nicotine cigarettes - Winston-Salem Journal
FDA Files MRTP Renewal for Two 22nd Century Products - Tobacco Reporter
XXII Q1 2026 Earnings Call Transcript - The Globe and Mail
MSN Money - MSN
Number of shareholders of 22nd Century Group, Inc – NASDAQ:XXII - TradingView
22Nd Century Group IncQ1 Net Revenues Incr - Moomoo
Q1 2026 22nd Century Group Inc Earnings Call Transcript - GuruFocus
22nd Century Group, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
22nd Century: Q1 Earnings Snapshot - theheraldreview.com
22nd Century Group 1Q Loss $3.3M >XXII - Moomoo
Earnings call transcript: 22nd Century Group reports Q1 2026 financials By Investing.com - Investing.com South Africa
XXII: Sequential revenue up 16% in Q1 2026 as VLN retail expansion accelerates - TradingView
Earnings call transcript: 22nd Century Group reports Q1 2026 financials - Investing.com India
22nd Century Group Releases Q1 2026 Financial Results - AlphaStreet
22nd Century Group, Inc. Stock (XXII) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):